Abstract | BACKGROUND: METHODS: To compare the clinical and the prognostic impact of both therapies, a study collective of n = 56 patients diagnosed with indolent B-cell lymphoma was retrospectively investigated. The study collective was subdivided into two groups: n = 36 patients treated with rituximab maintenance therapy vs n = 20 patients treated with 90 Y- ibritumomab-tiuxetan. RESULTS: No prognostic differences for performance status, FLIPI score, gender, or B-symptoms were found for 90 Y- ibritumomab-tiuxetan or rituximab maintenance therapy. Overall survival rates and progression-free survival did not differ between both maintenance therapies. CONCLUSION: Our retrospective single-center analysis of two patient groups without major differences in prognostic parameters revealed similar outcome with two different maintenance therapies. Hence, 90 Y- ibritumomab-tiuxetan therapy might offer a valuable alternative treatment option for FL patients with partial response. However, large prospective trials are needed to confirm the reported findings.
|
Authors | Eva U Spukti, Lars Henning Schmidt, Arik Schulze, Christoph Schliemann, Dennis Görlich, Eva Wardelmann, Wolfgang Hartmann, Georg Lenz, Wolfgang E Berdel, Andrea Kerkhoff |
Journal | European journal of haematology
(Eur J Haematol)
Vol. 101
Issue 4
Pg. 514-521
(Oct 2018)
ISSN: 1600-0609 [Electronic] England |
PMID | 29993147
(Publication Type: Journal Article)
|
Copyright | © 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. |
Chemical References |
- Antibodies, Monoclonal
- Immunoconjugates
- Yttrium Radioisotopes
- ibritumomab tiuxetan
|
Topics |
- Adult
- Aged
- Antibodies, Monoclonal
(administration & dosage, adverse effects, therapeutic use)
- Combined Modality Therapy
- Female
- Humans
- Immunoconjugates
(administration & dosage, adverse effects, therapeutic use)
- Lymphoma, Follicular
(mortality, pathology, therapy)
- Maintenance Chemotherapy
- Male
- Middle Aged
- Multimodal Imaging
- Neoplasm Staging
- Survival Analysis
- Treatment Outcome
- Yttrium Radioisotopes
(therapeutic use)
|